Jim Banting appointed president and CEO of PARTEQ
February 5, 2014
By Communications Staff
Jim Banting (Artsci’93, PhD’97) will become the new president and chief executive officer of PARTEQ Innovations in March.
“Dr. Banting possesses considerable business development expertise and connections that will enhance PARTEQ’s mission of supporting the development of marketable technologies based on the discoveries of Queen’s researchers,” says Steven Liss, Vice-Principal (Research) and chair of PARTEQ’s board of directors. “Dr. Banting’s own experience co-founding a Queen’s spin-off company will undoubtedly prove beneficial in this role.”
Dr. Banting has garnered over 15 years of experience in the life science sector. He will be transitioning from the head of business development position at Sigma-Tau Pharmaceuticals, a U.S. company focused on rare diseases.
Previously, Dr. Banting spent six years in the business development group of the U.S. biotechnology company Human Genome Sciences. In that role, he led the due diligence and negotiation of a number of in- and out-licensing, manufacturing, platform, and co-development related collaborations. Dr. Banting has also worked at the proteomics company Caprion, securing numerous biomarker discovery collaborations with industry partners.
“I am honoured to have the opportunity to work with the PARTEQ team, in continuing the mandate of serving as a catalyst for the partnering/commercialization of the world-class discoveries, inventions and technologies arising from the research conducted by Queen’s faculty, staff and surrounding partner institutions,” says Dr. Banting.
Dr. Banting graduated from Queen’s in 1993 with an honours degree in Life Sciences. He went on to earn his doctorate in pharmacology at Queen’s. His career began as a co-founder of the Queen’s spin-off company Vaxis Therapeutics that was funded by venture capitalists. After growing the company, Dr. Banting served as the business development lead on the sale of Vaxis to a U.S. speciality pharmaceutical company.